TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02607423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo 18F-FDG PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo 18F-FDG PET/CT
Study: NCT01926015

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP-IPV
Description: Diphtheria, tetanus, pertussis, inactivated polio vaccine used as part of the Japanese vaccination schedule
Study: NCT02607423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F-FDG PET/CT
Study: NCT01706861

Intervention type: DEVICE
Group type: OTHER
Intervention: Celotres
Description: Celotres following surgical removal of earlobe keloid.
Study: NCT00319046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miglustat
Description: Oral capsules containing miglustat 100 mg, administered three times daily (t.i.d.)
Study: NCT00265044

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Provider Education

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hypertension Alert

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient Education
Study: NCT03223454

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAECs
Description: hAECs are provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAECs
Description: hAECs are provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAECs
Description: hAECs are provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAECs
Description: hAECs are provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: biological amnion
Description: Biological amnion is purchased from JiangXi RuiJi BioTechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
Study: NCT03630094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEP-ZID
Description: A total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
Study: NCT04270006

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adipose derived stem cells exosomes
Description: they are small extracellular vesicles
Study: NCT02012231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX8394
Description: PLX8394 is a next-generation, orally available, small-molecule, selective inhibitor of BRAF.
Study: NCT04126330

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo generated for probiotic and omega-3/vitamin D supplements
Study: NCT01301196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational workshop
Description: 3h attendance at educational workshop plus self-monitoring
Study: NCT03814668

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Intake of probiotic
Study: NCT01729026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shelter Dog Adoption
Description: Veterans will choose a dog from the San Antonio Humane Society with the help a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
Study: NCT01266655

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02191241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Red Vine Leaf Extract
Study: NCT02205827

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Single-arm
Description: collection of blood for assessment of whole blood clotting time
Study: NCT03814668

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactase
Description: Intake of lactase

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intake of placebo
Study: NCT00915330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid on-site cytopathologic evaluation (ROSE)
Description: ROSE: examination in the endoscopy suite, by a pathologist, during the bronchoscopic procedure, of samples obtained with transbronchial needle aspiration.
Study: NCT01729026

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shelter Dog Adoption
Description: Veterans will choose a dog from the San Antonio Humane Society with the help a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
Study: NCT02153892

Intervention type: DEVICE
Group type: OTHER
Intervention: GDS Accucinch System
Description: Percutaneous Coronary Intervention
Study: NCT01915342

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal muscular vibration
Study: NCT00915330

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TBNA
Description: transbronchial needle aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TBNA
Description: transbronchial needle aspiration
Study: NCT00541125

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: bevacizumab

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: filgrastim

Intervention type: DRUG
Group type: OTHER
Intervention: fluorouracil
Study: NCT03711916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PlasmaBlade 3.0S
Description: PlasmaBlade (Medtronic) is approved by United States Food and Drug Administration (FDA) as a low thermal dissection device that has shown to be associated with effective cutting, and significantly lower temperature than traditional electrosurgical dissection devices.
Study: NCT00727077

Intervention type: BIOLOGICAL
Intervention: IntronA (interferon alfa-2b; SCH 30500)
Description: IntronA (3 Mio I.E./m2, 3 times per week) administered in accordance with the SPC and approved European labeling
Study: NCT02912949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zenocutuzumab (MCLA-128)
Description: full length IgG1 bispecific antibody targeting HER2 and HER3
Study: NCT00541125

Intervention type: DRUG
Group type: OTHER
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: OTHER
Intervention: leucovorin calcium
Study: NCT01983306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-333 1 mg
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-333 3 mg
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-333 6 mg
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study: NCT02072226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Single dose of alteplase will be administered at 0.9 milligrams per kilogram (mg/kg) IV (maximal dose of 90 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase Placebo
Description: Single dose of alteplase placebo will be administered as IV injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Single dose of aspirin will be administered at 325 mg orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Placebo
Description: Single dose of aspirin placebo will be administered orally.
Study: NCT04331873

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: An ultrasound will be obtained prior to obtaining the standard contrast injection to determine if this imaging modality is equivocal.
Study: NCT03776643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILT-101 ld-(IL2)
Description: Subcutaneous injections of ILT-101 or Placebo starting with once-daily administration for 5 consecutive days followed by once every two weeks administration during five months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ILT-101 ld-(IL2)
Description: Subcutaneous injections of ILT-101 or Placebo starting with once-daily administration for 5 consecutive days followed by once every two weeks administration during five months
Study: NCT04147832

Intervention type: OTHER
Intervention: Alert to provider
Description: Provider will receive an alert of sub-optimal patient attendance using 4 rules.
Study: NCT03771417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The use of exercise to improve muscle and cardiometabolic health in older adults.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: The use of exercise to improve muscle and cardiometabolic health in older adults.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: The use of exercise to improve muscle and cardiometabolic health in older adults.
Study: NCT02874404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative markers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative markers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative markers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K-delta Inhibitor TGR-1202
Description: Given PO
Study: NCT00727077

Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Rebetol (15 mg/kg/day) administered in accordance with the SPC and approved European labeling
Study: NCT01397981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait retraining
Description: Changing the kinematics of walking
Study: NCT03630419

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mito-Food Plan
Description: Specialized anti-inflammatory diet plan based on subject's physiological results

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cellular Repair Therapy
Description: the objective of this type of technology is to support the body's own processes to repair protein structures and maintain the health of the DNA, both of which have been damaged by internal and external factors.
Study: NCT01251939

Intervention type: DEVICE
Intervention: Near-infrared spectroscopy (NIRS)
Description: Non-invasive monitoring device measures the quantity of reflected light photons as a function of two wavelengths, and determines the spectral absorption of the underlying tissue.

Intervention type: DEVICE
Intervention: Near-infrared spectroscopy (NIRS)
Description: Non-invasive monitoring device measures the quantity of reflected light photons as a function of two wavelengths, and determines the spectral absorption of the underlying tissue.
Study: NCT03261362

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Branched-chain amino acids reduced intake

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Branched-chain amino acids reduced intake
Study: NCT04206722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock Wave Therapy
Description: Shock Wave therapy - hip osteoarthritis program

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound 0.7W/cm2
Study: NCT02512614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antimicrobial Hand Towel
Description: Novel antimicrobial hand towel.
Study: NCT04614597

Intervention type: BIOLOGICAL
Intervention: Sabin strain inactivated polio vaccine
Description: Sabin IPVs have been given to participants in previously study, blood specimens will be collected once all the subjects reach the age of 18months.

Intervention type: BIOLOGICAL
Intervention: Sabin strain inactivated polio vaccine
Description: Sabin IPVs have been given to participants in previously study, blood specimens will be collected once all the subjects reach the age of 18months.
Study: NCT03454711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Brain MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Brain MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry
Description: Resting energy expenditure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry
Description: Resting energy expenditure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioimpedance
Description: Measurement of body composition

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioimpedance
Description: Measurement of body composition

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipid profile, glucose, HBA1c, metabolomic analysis
Description: Blood sample

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipid profile, glucose, HBA1c, metabolomic analysis
Description: Blood sample

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YFAS questionnaire, Binge Eating Scale, Hospital Anxiety and Depression (HAD) scale, hedonic evaluation test (liking)
Description: Questionnaires to characterize eating habits and depression

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YFAS questionnaire, Binge Eating Scale, Hospital Anxiety and Depression (HAD) scale, hedonic evaluation test (liking)
Description: Questionnaires to characterize eating habits and depression
Study: NCT00955071

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise: LVLI
Description: low volume, low intensity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise: HVLI
Description: high volume, low intensity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise: LVHI
Description: low volume, high intensity
Study: NCT03479970

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GNPT+ Social Cognition
Description: Aplication of a computer based treatment focused on attention, memory, executive functions and social cognition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GNPT
Description: It's a computeritzed program of cognitive telerehabilitation
Study: NCT00976040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy
Description: The intervention is early initiation of antiretroviral therapy after diagnosis of Cryptococcal meningitis.~In the intervention/experimental arm, triple-drug highly active antiretroviral therapy regimens will be initiated within 7 days of diagnosis of Cryptococcal meningitis.
Study: NCT03986398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infection prophylaxis
Description: Infection prophylaxis with Urell®, cranberry fruit juice extract (vaccinium macrocarpon)
Study: NCT03692468

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Participants will complete 5, 60 minutes sessions. At each session, participants will learn strategies that have been shown to improve pain functioning and/or mood for patients who have chronic pain. The intervention will be delivered in the patient's primary care clinic.
Study: NCT03018769

Intervention type: DRUG
Intervention: Chinese Herb
Study: NCT01626456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 9072, Low
Description: IM injection, given monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 9072, High
Description: IM injection, given monthly
Study: NCT00813306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2066
Description: 13 mg oral solution, 1 single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution, 1 single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2066
Description: Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2066
Description: Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution, 1 single dose
Study: NCT03298906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will self-administer one intranasal spray of 14 mg esketamine at Time 0 and again 5 minutes later on Day 1, a total dose of 56 mg in Treatment Period 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Description: Participants will receive 250 mg ticlopidine tablets orally twice daily on Day -9 through Day 1 in Treatment Period 2.
Study: NCT00716703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT Scan using IV contrast alone
Description: CT scan using IV contrast alone
Study: NCT04068935

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fracture immobilization after reduction of displaced finger fractures
Description: After closed reduction of a displaced finger fracture, fracture immobilization with either Buddy taping or Splint immobilization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fracture immobilization after reduction of displaced finger fractures
Description: After closed reduction of a displaced finger fracture, fracture immobilization with either Buddy taping or Splint immobilization
Study: NCT01724918

Intervention type: DRUG
Group type: OTHER
Intervention: Lacosamide

Intervention type: DRUG
Group type: OTHER
Intervention: Lacosamide

Intervention type: DRUG
Group type: OTHER
Intervention: Lacosamide
Study: NCT04200950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Previse
Description: Machine learning algorithm for early acute kidney injury (AKI) prediction.
Study: NCT01397890

Intervention type: DRUG
Group type: OTHER
Intervention: Budesonide/formoterol (Symbicort® Turbuhaler®)
Description: Budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5μg/inhalation, 2 inhalations twice daily

Intervention type: DRUG
Group type: OTHER
Intervention: Tiotropium (SpirivaTM)
Description: Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily

Intervention type: DRUG
Group type: OTHER
Intervention: Tiotropium (SpirivaTM)
Description: Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily
Study: NCT00871533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFNα2b
Description: IV injection at 20 million IU/m2. IFNα2b IV injection will be performed every day between day -14 and day -9 (5 infusions) and also every day between day -7 and day -2 (5 infusions) for a total of 10 infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFNα2b
Description: SC injections peri-lesionally (PL) in the vicinity of the primary, at 10 million IU/m2. IFNα2b Injection will be performed every other day between day -14 and day -9 (3 injections) and also every other day between day -7 and day -2 (3 injections) for a total of 6 injections.
Study: NCT04156724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helmet vetilation
Description: We will apply non-invasive positive pressure ventilation via a helmet as interface
Study: NCT04481386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitargus, BFC-1401
Description: A single intravitreal (IVT) dose of BFC-1401 in participants as a vitreous substitute during vitrectomy surgery.
Study: NCT04246619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin Krka (pregabalin) hard capsules of different strenghts: 25 mg, 75 mg, 150 mg, 300 mg.~Duration: 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Dulsevia® (duloxetine) hard gastro-resistant capsules of different strenghts: 30 mg and 60 mg.~Duration: 12 weeks
Study: NCT01036113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EZN-2208
Description: EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
Study: NCT04069182

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Activation Therapy
Description: Behavioral Activation Therapy (BAT) has its origins in Cognitive Behavioral Therapy. In BAT, the patient monitors his emotions and daily activities, as a behavioral element. It seeks to increase the number of pleasant activities and increase interactions with the environment. The BAT considers positive reinforcement as the main intervention strategy. The treatment focuses on helping patients to systematically increase contact with their life's reward sources and solve their problems through procedures that focus on activation and on processes that inhibit it such as escape, avoidance behaviors and ruminant thoughts. It is a brief treatment consisting of 10 to 12 sessions spaced weekly (one hour per session), the first sessions are an explanation of the treatment and depression. Subsequent sessions are based on a collaborative work where the therapist and the patient work together to find activities that are according to the needs of the patient.